NYSE:NVO Novo Nordisk A/S Q1 2026 Earnings Report $39.44 -0.36 (-0.91%) Closing price 03:59 PM EasternExtended Trading$39.34 -0.09 (-0.23%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Novo Nordisk A/S EPS ResultsActual EPS$1.03Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANovo Nordisk A/S Revenue ResultsActual Revenue$10.85 billionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANovo Nordisk A/S Announcement DetailsQuarterQ1 2026Date3/31/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsNovo Nordisk A/S' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Novo Nordisk A/S Earnings HeadlinesNovo eyes hair-loss market as Ozempic maker looks to diversify2 hours ago | seekingalpha.comChronic Pain Market Poised for Growth at a CAGR of 5% During the Forecast Period (2026-2036), as Rising Patient Burden and Novel Treatment Approaches are Creating New Opportunities | DelveInsight2 hours ago | finance.yahoo.comIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed forces. One writer says the request echoes a secret January meeting outside Washington, D.C., where an anonymous source described American military protection as part of something much bigger, involving Trump, Iran, and potentially trillions of dollars.September 22 at 1:00 AM | Banyan Hill Publishing (Ad)European Markets Close Mixed Ahead of Trump-Xi Summit; Saudi Arabia Oil Pipeline Restarts2 hours ago | finance.yahoo.comNovo CEO says pills could capture 50% of weight-loss market by 2030September 22 at 11:16 AM | reuters.comViking Therapeutics Stock Surges 36%. It Could Challenge Lilly and Novo's Obesity Empire.September 22 at 8:22 AM | barrons.comSee More Novo Nordisk A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Novo Nordisk A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novo Nordisk A/S and other key companies, straight to your email. Email Address About Novo Nordisk A/SNovo Nordisk A/S (NYSE:NVO) is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders. Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies. Novo Nordisk’s products are marketed in numerous countries worldwide and are supported by research, manufacturing and commercial operations across multiple regions. Novo Nordisk was formed through the 1989 merger of Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium, two Danish companies that had developed insulin treatments in the early twentieth century. Maziar Mike Doustdar serves as president and chief executive officer, while Helge Lund serves as chair of the board of directors.View Novo Nordisk A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Meta’s Muse Highlights Arm’s Growing Role in AI InfrastructureNucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportDespite Record Sales, Texas Roadhouse Has Beef With Beef CostsEncore Capital Group Has Doubled—But Its Best Tailwind Won’t Last ForeverCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
